Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain;Análisis coste-utilidad del tratamiento de la esclerosis múltiple remitente-recidivante con azatioprina o interferón beta en España

Revista de Neurologia

Volumn 40, Issue 12, 2005, Pages 705-710

  Rubio Terrés, Carlos ^a   Dominguez Gil Hurle A ^b  

^a HERO Consulting   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Azathioprine. Beta interferon; Costs; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; COST OF ILLNESS; COST UTILITY ANALYSIS; FEMALE; HUMAN; LIFE EXPECTANCY; MULTIPLE SCLEROSIS; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SPAIN; UNIVARIATE ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH SERVICE; LONGEVITY; MALE; MIDDLE AGED; UTILIZATION REVIEW;

ADJUVANTS, IMMUNOLOGIC; AZATHIOPRINE; COST-BENEFIT ANALYSIS; FEMALE; HEALTH SERVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LONGEVITY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SPAIN;

EID: 26044478429     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4012.2004417     Document Type: Article

References (62)

1. Ryan M. Update on multiple sclerosis treatment. J Am Pharm Assoc 1996; 36: 419-20.
2. Noseworthy JH, Lucchinetti C, Rodríguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
3. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13: 119-46.
4. Reumont MJ, Deluca SA. Neuroimaging evaluation in multiple sclerosis. Am Fam Physician 1993; 48: 273-6.
5. Mallada J. Epidemiología de la esclerosis múltiple en España. Datos de prevalencia e incidencia. Rev Neurol 1999; 29: 864-7.
6. Izquierdo G, Navarro G, García-Moreno J, Durán E, Gamero M, Ruiz-Peña J, et al. Incidence of múltiple sclerosis in a nine-year period in the province of Seville (South-west Spain). Actrims/Ectrims 2002 meeting. Baltimore, 18-21 de Septiembre de 2002. Resumen P56. URL: http://www.actrimsectrims2002.nmss.org/images/meetingAbstract.pdf. Fecha última consulta: 30.04.2004.
7. Fernández O, Luque G, San Román C, Bravo M, Dean G. The prevalence of multiple sclerosis in the sanitary district of Velez-Málaga, Southern Spain. Neurology 1994; 44: 425-9.
8. Fernández O, Fernández VE. Esclerosis múltiple. URL: http://www.fedem.org/libro.html. Fecha última consulta: 30.04.2004.
9. Thompson AJ. Symptomatic management and rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71 (Suppl. 2): S22-7.
10. Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4: 1-103.
11. De Andrés C, Guillén A. Una aproximación sobre la calidad de vida en pacientes con esclerosis múltiple. Rev Neurol 2000; 30: 1229-34.
12. Martínez S, Martínez A, Hernández JJ. Impacto sociolaboral de la esclerosis múltiple. Neurología 1999; 14: 107-10.
13. Kobelt G, Lindgren P, Smala A, Bitsch A, Haupts M, Kölmel HW, et al. Costs and quality of life in multiple sclerosis. An observational study in Germany. HEPAC 2001; 2: 60-8.
14. Murphy N, Confavreux C, Haas J, König N, Roullet E, Sailer M, et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998; 13: 607-22.
15. Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 1998; 64: 444-50.
16. Otten N. Comparison of drug treatment for multiple sclerosis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1998.
17. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Multiple Sclerosis 2000; 6: 91-8.
18. Grudzinski AN, Hakim Z, Cox ER, Bootman JL. The economics of multiple sclerosis. Distribution of costs and relations to disease severity. Pharmacoeconomics 1999; 15: 229-40.
19. Prosser LA, Kuntz KM, Ber-Or A, Weinsteln MC. Cost-effectiveness of interferon beta-1A, interferon beta-1B, and glatiramer acetate in multiple sclerosis. Med Decis Making 2000; 20: 429.
20. Battaglia MA, Zagami P, Messner M. A cost evaluation of multiple sclerosis. J NeuroVirol 2000; 6 (Suppl 2): S191-3.
21. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Med Econ 1995; 8: 181-93.
22. Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A costutility analysis of interferon beta for multiple sclerosis. Health Technol Assessment 1998; 2: 1-67.
23. Bose U, Ladkani D, Burrell A, Sharief M. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 2001; 4: 207-19.
24. Phillips CJ, Gilmour L, Gale R, Palmer M. A cost utility model of interferon beta.1b in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 2001; 4: 35-50.
25. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value in Health 2002; 5: 44-54.
26. Jöhnsson B, Henriksson F. Economic burden of multiple sclerosis. Eur J Neurol 1998; 5 (Suppl 2): S35-7.
27. Medina F. Impacto de interferón beta en el tratamiento de la esclerosis múltiple en su forma remitente-recidivante y su correlación con la evolución de la enfermedad. Bases de datos de tesis doctorales (TESEO). URL: http://www.mcu.es/cgi-in/teseo/brscgi?cmd= verdoc&base=tseo&docn=000083022. Fecha última consulta: 30.04.2004.
28. Casado V, Martínez-Yelamos S, Martínez-Yelamos A, Carmona O, Hernández JJ, Arbizu T. A relapse of multiple sclerosis: how much does it cost in Catalonia? Actrims/Ectrims 2002 meeting. Baltimore, 18-21 de septiembre de 2002. Resumen P301. URL: http://www.actrimsectrims2002.nmss.org/ images/meetingAbstract.pdf. Fecha última consulta: 31.10.2002.
29. Rubio-Terrés C, Arístegui I, Medina F, Izquierdo G. Análisis costeutilidad del tratamiento de la esclerosis múltiple remitente-recidivante con acetato de glatiramero o interferón beta en España. Farm Hosp 2003; 27: 159-65.
30. Rubio-Terrés C. Introducción a la utilización de los modelos de Markov en el análisis farmacoeconómico. Farm Hosp 2000; 24: 241-7.
31. Instituto Nacional de Estadística. Anuario estadístico de España 2000. Madrid: INE; 2001.
32. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RAC, McPherson K, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5.
33. Swinburn WR, Liversedge LA. Long-term treatment of multiple sclerosis with azathioprine. J Neurol Neurosurg Psychiatry 1973; 36: 124-6.
34. Mertin J, Rudge P, Kremer M, Healey MJ, Knight SC, Compston A, et al. Double-blind controlled trial of immunosupression in the treatment of multiple sclerosis: final report. Lancet 1982; 2: 351-4.
35. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988; 2: 179-83.
36. Milanese C, La Mantia L, Salmaggi A, Campi A, Bortolami C, Tajoli L, et al. Double blind, controlled, randomised study on azathioprine efficacy in multiple sclerosis: preliminary results. Ital J Neurol Sci 1988; 9: 53-7.
37. Gonsette RE, Delmotte P, eds. Recent advances in multiple sclerosis therapy. Amsterdam: Elsevier; 1989.
38. Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989; 39: 1018-26.
39. Steck AJ, Regli F, Oschner F, Gauthier G. Cyclosporine vesus azathioprine in the treatment of multiple sclerosis: 12-month clinical and immunological evaluation. Eur Neurol 1990; 30: 224-8.
40. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991; 41: 20-5.
41. PRIMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
42. The IFNB, Multiple Sclerosis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
43. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
44. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78.
45. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-46.
46. Centro Nacional de Epidemiología. Mortalidad por causa, sexo y grupo de edad (CIE6). España, 1998. URL: http://193.146.50.130. Fecha última consulta: 30.04.2004.
47. Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. New York: Oxford University Press; 1994.
48. Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 1995; 8: 245-52.
49. Canadian Coordinating Office for Health Technology Assessment. Guideline for economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
50. Base de datos de medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos. Disponible en URL: http://www.portalfarma.com. Fecha última consulta: 30.04.2004.
51. Azanza JR, Cameán M, Cercós AC, Domínguez-Gil A, Escribá J, Gobernado M. Consenso sobre el diseño de un modelo farmacoeconómico útil para la valoración de antibióticos parenterales de uso hospitalario. Rev Esp Farmacoeconomía 1997; 3: 35-49.
52. Lhermitte F, Marteau R, Roullet E, de Saxce H, Loridan M. Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience. Rev Neurol (Paris) 1984; 140: 553-8.
53. Amato MP, Pracucci G, Ponziani G, Siracusa G, Fratiglioni L, Amaducci L. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993; 43: 831-3.
54. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a casecontrol study. Neurology 1996; 46: 1607-12.
55. Martínez F, Nos P, Pastor M, Garrigues V, Ponce J. Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Rev Esp Enferm Dig 2001; 93: 769-78.
56. Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol 2003; 98: 1305-8.
57. Prieto JM, Lema M. Interferón β en la esclerosis múltiple. Rev Neurol 2003; 36: 980-90.
58. Río J, Marzo ME, Tintoré M, Borrás C, Montalbán X. Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon beta-1b. Neurología 1998; 13: 422-6.
59. o 32. London: National Institute for Clinical Excellence; 2002.
60. Thomas FJ, Hughes TA, Anstey A. Azathioprine treatment in multiple sclerosis; pretreatment assessment of metaboliser status. J Neurol Neurosurg Psychiatry 2001; 70: 815.
61. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gaceta Sanitaria 2002; 16: 334-43.
62. Medina-Redondo F, Herrera-Carranza J, Sanabria C, Navarro G, García-Moreno JM, RES HASTA 6, et al. Eficiencia y relación coste-utilidad del interferón beta en la esclerosis múltiple en Andalucía. Rev Neurol 2004; 39: 1-6.